Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 0264 • ACR Convergence 2021
Joint Acoustic Emissions as a Biomarker to Differentiate Between Active and Inactive Juvenile Idiopathic Arthritis via 2-stage Machine Learning Classifier
Luis Rosa¹, Sevda Gharehbaghi¹, Omer Inan¹, Daniel Whittingslow², Lori Ponder³ and Sampath Prahalad⁴, ¹Georgia Institute of Technology, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA, ³Children's Healthcare of Atlanta, Atlanta, GA, ⁴Emory + Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most prevalent chronic rheumatic disease and can result in disability in children. JIA most commonly affects the knee.…
Abstract Number: 1639 • ACR Convergence 2021
A Comparison of Cardiovascular Health Indicators in Children with Juvenile Idiopathic Arthritis Who Meet and Do Not Meet the Physical Activity Guidelines
Madelyn Byra¹, Nicole Proudfoot², Si Ru Chen¹, Maureen MacDonald³, Tania Cellucci⁴, Michelle Batthish⁵, Brian Timmons⁶ and Joyce Obeid⁶, ¹Child Health & Exercise Medicine Program, McMaster University, Hamilton, ON, Canada, ²Child Health & Exercise Medicine Program, McMaster University; Department of Kinesiology, McMaster University, Hamilton, ON, Canada, ³Department of Kinesiology, McMaster University, Hamilton, ON, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶Child Health & Exercise Medicine Program, McMaster University; Department of Pediatrics, McMaster University, Hamilton, ON, Canada
Background/Purpose: Children with juvenile idiopathic arthritis (JIA) engage in less physical activity than their healthy peers. The Canadian 24-h Movement Guidelines recommend children take part…
Abstract Number: 0247 • ACR Convergence 2021
Three-year Effectiveness in Patients with JIA Initiating Abatacept: Results from the PRCSG/PRINTO JIA Real-World Registry
Nicolino Ruperto¹, Hermine Brunner², Nikolay Tzaribachev³, Ilonka Orbán⁴, Valda Staņēviča⁵, Ana Quintero del Rio⁶, Pierre Quartier⁷, Adam Huber⁸, Dan Kietz⁹, Jason Dare¹⁰, Daniel Kingsbury¹¹, T. Brent Graham¹², Ivan Foeldvari¹³, Julisa Patel¹⁴, Alyssa Dominique¹⁵, Lixian Dong¹⁵, Tzuyung Douglas Kou¹⁵, Robert Wong¹⁶, Alberto Martini¹⁷ and Daniel Lovell¹⁸, ¹IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³PRI Research, Bad Bramstedt, Germany, ⁴National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ⁵Riga Stradins University, Riga, Latvia, ⁶Dr. Ramon Ruiz Arnau University Hospital, Bayamόn, PR, ⁷Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, ⁸Dalhousie University, Halifax, NS, Canada, ⁹Children’s Hospital of Pittsburgh, Pittsburg, PA, ¹⁰University of Arkansas for Medical Sciences, Little Rock, AR, ¹¹Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹²Vanderbilt University Medical Center, Nashville, TN, ¹³Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ¹⁴Children’s Hospital of Georgia, Augusta University Medical Center, Augusta, GA, ¹⁵Bristol Myers Squibb, Princeton, NJ, ¹⁶Bristol Myers Squibb, Basking Ridge, NJ, ¹⁷Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ¹⁸Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH
Background/Purpose: The ongoing phase 4 Pediatric Rheumatology Collaborative Study Group (PRCSG)/Paediatric Rheumatology INternational Trials Organisation (PRINTO) registry was designed to assess the long-term (up to…
Abstract Number: 0265 • ACR Convergence 2021
Development and Preliminary Acceptability of JIActiv, a Social Media-Based Program Promoting Engagement in Physical Activity Among Young People Living with Juvenile Idiopathic Arthritis
Sabrina Cavallo¹, Karine Toupin April², Ciaran Duffy², Karina Cristea¹, Jihene Tlili¹, Imane Brahmi¹, Zeinab Ahmadian¹, Michele Gibbon³, Alexandra Sirois⁴, Laurie Proulx⁵, Sara Ahmed⁶, Claudine Auger¹ and Jennifer Stinson⁷, ¹Université de Montréal, Montréal, QC, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ⁴Canadian Arthritis patient Alliance, Montréal, QC, Canada, ⁵Canadian Arthritis Patient Alliance, Ottawa, ON, Canada, ⁶Children's Hospital of Eastern Ontario, Montréal, QC, Canada, ⁷The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Young people with juvenile idiopathic arthritis (JIA) are at greater risk for adopting chronic sedentary behaviours and not meeting national physical activity guidelines compared…
Abstract Number: 1927 • ACR Convergence 2021
Heterogeneity of Juvenile Idiopathic Arthritis Synovial Fibroblasts Correlates to Disease Progression and Provides Compelling Diagnostic Data
Megan Simonds¹, Kathleen Sullivan², Carlos Rose³ and AnneMarie Brescia⁴, ¹Nemours, Wilmington, DE, ²The Children's Hospital of Philadelphia, Philadelphia, PA, ³Thomas Jefferson University/duPont Hospital for Children, Wilmington, DE, ⁴Nemours/A.I.duPont Hospital for Children, Wilmington, DE
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) induces growth disturbances in affected joints. Fibroblast-like synoviocytes (FLS) play a crucial role in JIA pathogenesis; however, the mechanisms by…
Abstract Number: 0248 • ACR Convergence 2021
Proportion of Patients with a Polyphasic Disease Course in Systemic-onset Juvenile Idiopathic Arthritis May Be Higher in the Age of Cytokine Inhibitors
Itay Marmor¹, Rotem Semo Oz², Amir Hendel³, Guy Hazan¹, Kevin Baszis⁴, Anthony French¹, Cuoghi Edens⁵, irit Tirosh⁶, Yonatan Butbul Aviel⁷, Liora Harel⁸ and Gil Amarilyo⁹, ¹Washington University School of Medicine, St. Louis, MO, ²Sheba Medical Center, Herzelyia, Israel, ³Sackler Faculty of Medicine, Tel Aviv University; Clalit Health Services, Sharon and Shomron County, Tel Aviv, Israel, ⁴Washington University School of Medicine, St Louis, MO, ⁵University of Chicago, Chicago, IL, ⁶Sheba Medical Center, Ramat Gan, Israel, ⁷Rambam Medical center, Haifa, Israel, ⁸Scheiders Children Medical Center of Israel, Petah-Tiqva, Israel, ⁹Schneider Children's Medical Center of Israel, Kibbutz Maggal, Israel
Background/Purpose: Systemic-onset juvenile idiopathic arthritis (sJIA) is a pediatric autoinflammatory condition, known for significant variability between patients in its severity and long-term outcomes. The classification…
Abstract Number: 0658 • ACR Convergence 2021
ACCORD: A Novel Rheumatology Transition Clinic Structure for Adolescent and Young Adult Patients with Childhood Onset Rheumatic Disease
Rebecca Overbury¹, Kelly Huynh², Tracy Frech¹, John Bohnsack¹ and Aimee Hersh¹, ¹University of Utah, Salt Lake City, UT, ²Intermountain Health Care, Salt Lake City, UT
Background/Purpose: The transition of health care from Pediatric to Adult providers for adolescents and young adults with childhood onset rheumatic disease continues to be associated…
Abstract Number: 1930 • ACR Convergence 2021
Single-Cell Genomics Reveals a Shared Monocyte Interferon Program in a Subset of Patients with Systemic Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome and Lung Disease
Emely Verweyen¹, Kairavee Thakkar², Kashish Chetal², Sanjeev Dhakal³, Alexei Grom², Nathan Salomonis² and Grant Schulert², ¹Cincinnati Children's Hospital, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children hospital, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a clinically heterogenous disease and can be complicated by macrophage activation syndrome (MAS) and lung disease (LD) thought…
Abstract Number: 0249 • ACR Convergence 2021
Open-label, Long-term (10-year) Study of the Safety of Etanercept in Children with Extended Oligoarticular Arthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis
Jelena Vojinović¹, Joke Dehoorne², Violeta Panaviene³, Gordana Susic⁴, Gerd Horneff⁵, Valda Stanevicha⁶, Katarzyna Kobusinska⁷, Zbigniew Zuber⁸, Bogna Dobrzyniecka⁹, Jonathan Akikusa¹⁰, Tadej Avcin¹¹, Alberto Martini¹², Cecilia Borlenghi¹³, Edmund Arthur¹⁴, Svitlana Tatulych¹⁵, Chuanbo Zang¹⁶, Bonnie Vlahos¹⁶ and Nicolino Ruperto¹⁷, ¹Paediatric Rheumatology International Trials Organisation (PRINTO), Nis, Serbia, ²Paediatric Rheumatology International Trials Organisation (PRINTO), Gent, Belgium, ³Paediatric Rheumatology International Trials Organisation (PRINTO), Vilnius, Lithuania, ⁴Paediatric Rheumatology International Trials Organisation (PRINTO), Belgrade, Serbia, ⁵Paediatric Rheumatology International Trials Organisation (PRINTO), Sankt Augustin, Germany, ⁶Paediatric Rheumatology International Trials Organisation (PRINTO), Riga, Latvia, ⁷Paediatric Rheumatology International Trials Organisation (PRINTO), Bydgoszcz, Poland, ⁸Paediatric Rheumatology International Trials Organisation (PRINTO), Lodz, Poland, ⁹Paediatric Rheumatology International Trials Organisation (PRINTO), Warsaw, Poland, ¹⁰Paediatric Rheumatology International Trials Organisation (PRINTO), Melbourne, Australia, ¹¹Paediatric Rheumatology International Trials Organisation (PRINTO), Ljubljana, Slovenia, ¹²Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ¹³Pfizer, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁴Pfizer, Peapack, NJ, ¹⁵Pfizer, Groton, CT, ¹⁶Pfizer, Collegeville, PA, ¹⁷IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy
Background/Purpose: CLIPPER2 was an 8-year, open-label extension of the phase 3b, multicenter, 2-year CLIPPER study of the safety and efficacy of etanercept (ETN) in the…
Abstract Number: 0960 • ACR Convergence 2021
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: 24-Month Outcomes
Yukiko Kimura¹, Sarah Ringold², George Tomlinson³, Laura Schanberg⁴, Anne Dennos⁵, Mary Ellen Riordan⁶, Vincent Del Gaizo⁷, Katherine Murphy⁸, Pamela Weiss⁹, Brian Feldman¹⁰, Marc Natter¹¹ and The STOP-JIA CARRA Registry Investigators¹², ¹Hackensack University Medical Center, New York, NY, ²Seattle Children's Hospital, Seattle, WA, ³University of Toronto, Toronto, ON, Canada, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Hackensack University Medical Center, Westwood, NJ, ⁷Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁸Childhood Arthritis & Rheumatology Research Alliance (CARRA), New Orleans, LA, ⁹Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰The Hospital for Sick Children, Toronto, ON, Canada, ¹¹Boston Children's Hospital, Boston, MA, ¹²Childhood Arthritis & Rheumatology Research Alliance (CARRA), Milwaukee, WS
Background/Purpose: The CARRA STOP-JIA study compared the effectiveness of the CARRA Consensus Treatment Plans (CTPs) in achieving clinical inactive disease (CID) in untreated polyarticular JIA…
Abstract Number: PP09 • ACR Convergence 2021
Family Planning while Living with Rheumatoid Arthritis
Shannan O'Hara-Levi, Monroe, NY
Background/Purpose: Over the course of my 30+ years living with Polyarticular Juvenile Rheumatoid Arthritis, I have never had long term success on any one biologic treatment,…
Abstract Number: 0251 • ACR Convergence 2021
A Comparative Study of the Validity of the DAS28-ESR and JADAS-27 Disease Activity Assessment Indexes for Juvenile Idiopathic Arthritis in Transition and Adults
Takako Miyamae¹, Eiichi Tanaka¹, Eisuke Inoue², Katsunori Ikari¹ and Masayoshi Harigai³, ¹Tokyo Women's Medical University, Tokyo, Japan, ²Showa University, Tokyo, Japan, ³Tokyo Women's Medical University School of Medicine, Tokyo, Japan
Background/Purpose: The 2020 Rheumatoid Arthritis Clinical Practice Guidelines by the Ministry of Health, Labour, and Welfare Research Group recommends the JADAS27 as a measure of…
Abstract Number: 0976 • ACR Convergence 2021
Cumulative Social Disadvantage Predicts an Arthritis Diagnosis: A Cross-sectional Analysis of the National Survey of Children’s Health (NSCH)
William Soulsby, Erica Lawson and Matthew Pantell, University of California San Francisco, San Francisco, CA
Background/Purpose: The impact of social determinants of health in juvenile idiopathic arthritis (JIA) remains poorly understood. Racial disparities exist in JIA, including increased pain and…
Abstract Number: PP11 • ACR Convergence 2021
“Our Arthritis May Be Chronic but We Are Definitely Iconic” – Two Teens Created a National Podcast for Youth with Rheumatic Diseases
Trishtha Peters¹ and Natasha Trehan², ¹University of Ontario, Toronto, ON, Canada, ²University of Ottawa, Toronto, ON, Canada
Background/Purpose: Trish Peters was diagnosed with JIA at 11. She has been on Methotrexate to lessen disease activity for her knees and hands. She does…
Abstract Number: 0253 • ACR Convergence 2021
Rheumatoid Factor Status as a Predictor of Disease Activity and Disability:An Analysis of the New CARRA Registry Polyarticular Juvenile Idiopathic Arthritis Cohort
Nayimisha Balmuri¹, William Soulsby², Victoria Cooley³, Linda Gerber⁴, Erica Lawson² and Karen Onel¹, ¹Hospital for Special Surgery, New York, NY, ²University of California San Francisco, San Francisco, CA, ³Weil Cornell Medicine, New York, NY, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: Children with rheumatoid factor (RF) positive polyarticular JIA (pJIA) are less likely to go into remission and more likely to develop erosive disease than…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.